Docoh
Loading...

NMTR 9 Meters Biopharma

News

From Benzinga Pro
9 Meters Biopharma Q3 EPS $(0.05) Up From $(0.06) YoY
15 Nov 21
Earnings, News
9 Meters Biopharma (NASDAQ:NMTR) reported quarterly losses of $(0.05) per share. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
A Look Into Healthcare Sector Value Stocks
8 Nov 21
News
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
26 Oct 21
Biotech, Earnings, News, Penny Stocks, Health Care, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Overview Of Value Stocks In The Healthcare Sector
25 Oct 21
News
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
Overview Of Value Stocks In The Healthcare Sector
4 Oct 21
News
What is a Value Stock?
9 Meters Biopharma, Inc. Announces Partnership With Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
27 Sep 21
News, Contracts
9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today
5 Value Stocks In The Healthcare Sector
20 Sep 21
News
What Defines a Value Stock?

Press releases

From Benzinga Pro
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
15 Nov 21
Earnings, Press Releases
- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 -- Larazotide Phase 3 for celiac disease interim analysis expected
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
10 Nov 21
Contracts, Press Releases
Collaboration builds upon previous positive preclinical data warranting further investigation of NM-102, a potential novel therapy to enhance immune checkpoint inhibitor effectIND-enabling pathway for NM-102 underway
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
9 Nov 21
Events, Press Releases
In-Person Dates: November 16th-17thVirtual Dates: November 18th-19thRALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
26 Oct 21
Events, Press Releases
- Vurolenatide's half-life is consistent with twice-monthly dosing -- Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end -RALEIGH, NC / ACCESSWIRE / October 26, 2021 / 9
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
19 Oct 21
Events, Press Releases
RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
4 Oct 21
News, Press Releases
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
27 Sep 21
Contracts, Press Releases
RALEIGH, NC / ACCESSWIRE / September 27, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive
9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference
22 Sep 21
Events, Press Releases
- Conference Dates: September 27th-30th -RALEIGH, NC / ACCESSWIRE / September 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today
9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 Sep 21
Events, Press Releases
Conference Dates: September 20th-23rdRALEIGH, NC / ACCESSWIRE / September 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced